Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated
protein 4 expressions together with
clinicopathological findings in clear cell, papillary,
and chromophobe types of renal cell carcinoma

Merve Inceman; Tugba Toyran; Yildirim Bayazit; Volkan Izol; Seyda Erdogan

doi:10.5114/pjp.2022.122613

eISSN: 2084-9869
ISSN: 1233-9687

Polish Journal of Pathology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2022
vol. 73

Send email

Copy url:

abstract:

Original paper

Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated protein 4 expressions together with clinicopathological findings in clear cell, papillary, and chromophobe types of renal cell carcinoma

Merve Inceman

¹

,

Tugba Toyran

¹

,

Yildirim Bayazit

²

,

Volkan Izol

²

,

Seyda Erdogan

¹

Department of Pathology, Cukurova University Faculty of Medicine, Adana, Turkey
Department of Urology, Cukurova University Faculty of Medicine, Adana, Turkey

Pol J Pathol 2022; 73 (3): 181-190

DOI: https://doi.org/10.5114/pjp.2022.122613

Online publish date: 2022/12/17

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Inceman M, Toyran T, Bayazit Y, Izol V, Erdogan S. Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated
protein 4 expressions together with
clinicopathological findings in clear cell, papillary,
and chromophobe types of renal cell carcinoma. Polish Journal of Pathology. 2022;73(3):181-190. doi:10.5114/pjp.2022.122613.

APA

Inceman, M., Toyran, T., Bayazit, Y., Izol, V.,  & Erdogan, S. (2022). Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated
protein 4 expressions together with
clinicopathological findings in clear cell, papillary,
and chromophobe types of renal cell carcinoma. Polish Journal of Pathology, 73(3), 181-190. https://doi.org/10.5114/pjp.2022.122613

Chicago

Inceman, Merve, Tugba Toyran, Yildirim Bayazit, Volkan Izol,  and Seyda Erdogan. 2022. "Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated
protein 4 expressions together with
clinicopathological findings in clear cell, papillary,
and chromophobe types of renal cell carcinoma". Polish Journal of Pathology 73 (3): 181-190. doi:10.5114/pjp.2022.122613.

Harvard

Inceman, M., Toyran, T., Bayazit, Y., Izol, V.,  and Erdogan, S. (2022). Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated
protein 4 expressions together with
clinicopathological findings in clear cell, papillary,
and chromophobe types of renal cell carcinoma. Polish Journal of Pathology, 73(3), pp.181-190. https://doi.org/10.5114/pjp.2022.122613

MLA

Inceman, Merve et al. "Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated
protein 4 expressions together with
clinicopathological findings in clear cell, papillary,
and chromophobe types of renal cell carcinoma." Polish Journal of Pathology, vol. 73, no. 3, 2022, pp. 181-190. doi:10.5114/pjp.2022.122613.

Vancouver

Inceman M, Toyran T, Bayazit Y, Izol V, Erdogan S. Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated
protein 4 expressions together with
clinicopathological findings in clear cell, papillary,
and chromophobe types of renal cell carcinoma. Polish Journal of Pathology. 2022;73(3):181-190. doi:10.5114/pjp.2022.122613.

PlumX metrics:

Our study aimed to determine the expressions of programmed death protein 1 (PD-1), programmed death ligand protein 1 (PD-L1), and cytotoxic T-lymphocyte- associated protein 4 (CTLA-4) to investigate and compare the differences between early and advanced cases in the 3 most common types of renal cell carcinoma (RCC) and reveal their correlations with prognosis and survival. A total of 166 RCC cases diagnosed between 2010 and 2019 in our hospital were included. PD-1, PD-L1, and CTLA-4 markers were applied to the paraffin blocks of the cases using an immunohistochemical method, and their expression status was evaluated by distinguishing subtypes in advanced- and early-stage RCCs. It was observed that PD-L1 positivity in the tumour cells, in clear cell RCC, was statistically significantly more frequent in advanced-stage cases compared to early-stage cases. It was concluded that cases with PD-L1 positivity in tumour- infiltrating mononuclear cells (TIMC) in clear cell and chromophobe RCC had a shorter survival. The frequency of perinephritic fat invasion and necrosis was higher in cases with PD-L1 expression in TIMC. We think that PD-1, PD-L1, and CTLA-4 must be considered together in advanced stage RCC for the treatment of both pathway inhibitors. Further large studies will shed light on the immunotherapy options at the advanced stage of all RCC types even in the absence of metastasis.

keywords:

Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated protein 4 expressions together with clinicopathological findings in clear cell, papillary, and chromophobe types of renal cell carcinoma

Merve Inceman 1 , Tugba Toyran 1 , Yildirim Bayazit 2 , Volkan Izol 2 , Seyda Erdogan 1

renal cell carcinoma, PD-1, PD-L1, CTLA-4

Merve Inceman

¹

,

Tugba Toyran

¹

,

Yildirim Bayazit

²

,

Volkan Izol

²

,

Seyda Erdogan

¹